Compare BRAG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRAG | LGVN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Canada | United States |
| Employees | N/A | 38 |
| Industry | Office Equipment/Supplies/Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 34.0M |
| IPO Year | 2021 | 2021 |
| Metric | BRAG | LGVN |
|---|---|---|
| Price | $1.73 | $1.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 32.8K | ★ 9.2M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.13 | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.46 | $0.48 |
| 52 Week High | $4.82 | $1.83 |
| Indicator | BRAG | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 62.58 |
| Support Level | $1.56 | $0.55 |
| Resistance Level | $2.22 | $1.22 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 26.70 | 72.97 |
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, the United States, Croatia, and other regions.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.